Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America

Bayer105 enrolled

Overview

The aim of this international prospective post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of KOGENATE Bayer/FS in treatment of patients with haemophilia A under daily-life treatment conditions.

Study Type

OBSERVATIONAL

Enrollment

105

Conditions

Blood Coagulation Disorders Hemophilia A

Interventions

Recombinant Factor VIII (Kogenate FS, BAY14-2222)BIOLOGICAL

Patients under daily life treatment receiving Kogenate according to local drug information.

Eligibility

Sex: MALE

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with diagnosis of hemophilia A, independent of age, treated with KOGENATE® FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE® FS. For pretreated patients with more than 100 exposure days an inhibitor assessment within three months prior to enrollment should be available; for pretreated patients with less than 100 exposure days an inhibitor assessment at baseline should be available.

Locations (2)

Unnamed facility

Many Locations, Mexico

Unnamed facility

Many Locations, Venezuela